Diabetes Typ 2 mellitus und Krebs - eine ernährungsorientierte Interventionsstudie

Zusammenfassung

Mehrere kürzlich publizierte Studien zeigen immer deutlicher, dass das sog. „metabolische Syndrom” das Risiko, Tumore des Kolons, des Pankreas, der Brust, der Leber und der Gallenblase zu entwickeln, signifikant erhöht; die molekularbiologischen Hinweise dafür, warum Adipositas, Diabetes mellitus, Hyperinsulinämie und Insulinresistenz mit der Tumorgenese verbunden sein können, sind evident. Die großen amerikanischen Gesellschaften - American Cancer Society, American Diabetes Association, American Heart Association - haben in jüngster Zeit eindringlich darauf hingewiesen, gemeinsame Anstrengungen zu unternehmen, dieser existenziellen Herausforderung aus ärztlich-ethischen und ökonomischen Gründen bald zu begegnen. Zudem wird der Tumorpatient, der hinsichtlich der Primärerkrankung erfolgreich therapiert wurde, in seinen anderen Krankheitsbildern weniger wahrgenommen. Hier wird eine Feldstudie vorgestellt, die in Ergänzung zu einer standardsetzenden Studie der Gewichtsreduktion [[7]] zeigt, dass in einer ernährungsphysiologischen Intervention mit einer Soja-Honig-Magermilch-Joghurt-Formulierung gerade jene hormonellen (Insulin, Il-6, Adiponektine) und biochemischen (Glukose, Triglyzeride) Parameter des „metabolischen Syndroms” sanalogisch beeinflusst werden können, die eine Verbindung zur Karzinogenese herstellen.

Summary

Several studies have suggested that the metabolic syndrome may alter the risk of developing a variety of cancers - colon, pancreas, breast, liver, gall bladder - and the associations are biologically plausible. The American key societies - Cancer Society, Diabetes and Heart Associations - have stated that the current approaches to health promotion and prevention of cardiovascular disease, cancer and diabetes do not approach the potential of existing knowledge. A concerted effort to increase application of public health and clinical interventions of known efficacy could substantially reduce the human and economic costs of these diseases. Moreover, cancer survivors receive less care for other medical conditions. In addition to a scientifically trend setting weight reduction study [[7]] we introduce here data of a dietary intervention study in non-insulin dependent diabetes mellitus (NIDDM), showing that a regular support for 26 weeks of the day-to-day eating habit with a high-soy-protein/honey/milk/yoghurt formulation (Almased^®, Bienenbüttel, Germany, St. Petersburg, USA) down-regulates hormone (insulin, IL-6) and biochemical (fasting glucose, trigliceride level) parameters which may contribute to the carcinogenic process.

Schüsselwörter

Metabolisches Syndrom - Adipositas - Adipozyt - Adipokine - Hyperinsulinämie - Insulinresistenz - Krebs - Sojaprotein-Honig-Magermilch-Joghurt-Formulierung - Interventionsstudie

Keywords

Metabolic syndrome - adipositas - adipocyte - adipokine - hyperinsulinaemia - insulin resistance - cancer - high-soy-protein/honey/milk/yoghurt diet - intervention study

Literatur

• 01 Augustin L S, Dal Maso L, Franceschi S. et al . Association between components of the insulin-like growth factor system and endometrial cancer risk. Oncology.  2004;  67 54-59
• 02 Batty G D, Shipley M J, Marmot M. et al . Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study.  Cancer Causes Control. 2004;  15 873-881
• 03 Berstein L M, Kvatchevskaya J O, Poroshina T E. et al . Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer.  Cancer Res Clin Oncol. 2004;  (Epub ahead of print) 
• 04 Clark A M, Raine K, Raphael D. The American Cancer Society, American Diabetes Association, and American Heart Association joint statement on preventing cancer, cardiovascular, and diabetes: where are the social determinants?.  Diabetes Care. 2004;  27 3024
• 05 Coker A L, Sanderson M, Zheng W. et al . Diabetes mellitus and prostate cancer risk among older men: population-based case-control study.  Br J Cancer. 2004;  90 2171-2175
• 06 Coughlin S S, Calle E E, Teras L R. et al . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.  Am J Epidemiol. 2004;  15 1160-1167
• 07 Deibert P, König D, Schmidt-Trucksäss A. et al . Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet.  Int J Obes Relat Metab Disord. 2004;  28 1349-1352
• 08 Evert M, Sun J, Pichler S. et al . Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepatocarcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats.  Cancer Res. 2004;  64 8093-8100
• 09 Eyre H, Kahn R, Roberstson R M. et al . Preventing cancer, cardiovascular diseases, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Collaborative Writing Committee.  Stroke. 2004;  35 1999-2010
• 10 Folsom A R, Anderson K E, Sweeney C. et al: . Diabetes as a risk factor for death following endometrial cancer.  Gynecol Oncol. 2004;  94 740-745
• 11 Khaw K T, Wareham N, Bingham S. et al . Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis form the European prospective investigation into cancer-Norfolk study.  Cancer Epidemiol Biomarkers Prev. 2004;  13 915-919
• 12 Laukkanen J A, Laaksonen D E, Niskanen L. et al . Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study.  Cancer Epidemiol Biomarkers Prev. 2004;  13 1646-1650
• 13 Leon-Sanz M, Garcia-Luna P P, Sanz-Paris A. et al . Glycemic and lipid control in hospitalized Type 2 diabetic patients: evaluation of 2 enteral nutrition formulas (low carbohydrate-high mono-unsaturated fat vs high carbohydrate.  J Parenter Enteral Nutr. 2005;  29 21-29
• 14 Lin Y, Berg A H, Iyengar P. et al . The hyperglycemia-induced inflammatory response in adipocytes: The role of reactive oxygen species.  J Biol Chem. 2004;  (Epub ahead of print) 
• 15 Nelson R. Cancer survivors receive less care for other medical conditions.  Lancet Oncol. 2004;  5 646
• 16 Prentice R L. Chronic disease prevention: public health potential and research needs.  Stat Med. 2004;  23 3409-3420
• 17 Resta F, Triggiani V, Sabba C. et al . The impact of body mass index and type 2 diabetes on breast cancer: current therapeutic measures of prevention.  Curr Drug Targets Immune Endocr Metabol Disord. 2004;  4 327-333
• 18 Roberts C K, Barnard R J. Effects of exercise and diet on chronic disease.  J Appl Physiol. 2005;  98 3-30
• 19 Roomi M w, Ivanov v, Kalinovsky T. et al . Antitumour effect of nutrient synergy in human osteosarcoma cells U-2OS, MNNG-HOS and EwingŽs sarcoma SK-ES.1.  Oncol Rep. 2005;  13 253-257
• 20 Rose D P, Komninou D, Stephenson G D. Obesity, adipocytokines, and insulin resistance in breast cancer.  Obes Rev. 2004;  5 153-165
• 21 Yang Y X, Hennessy S, Lewis J D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.  Gastroenterology. 2004;  12 1044-1050
• 22 Zänker K s, Daftary g V, Gottschalk G. et al . Genistein and Daidzein: Mode of action and bioavailability as chemopreventive agents in a soy-enriched diet.  Dtsch Z Onkol. 2001;  33 37-44
• 23 Zänker K S, Gottschalk G, Adlercreutz H. Phase I trial with an isoflavonoid rich soy/milk/honey supportive nutrition for including into therapy-optimizing-protocols in oncology.  Dtsch Z Onkol. 2001;  33 136-139

Korrespondenzadresse